Tag: river blindness

Moxidectin, First New Treatment for River Blindness in 30 Years, Approved by FDA

The US FDA has approved the antihelminthic drug moxidectin (developed by Medicines Development for Global Health) for the treatment of onchocerciasis.¹

Merck’s ivermectin, developed in the late 1970s, is the only other pharmaceutical agent approved for treating onchocerciasis.  Moxidectin has outperformed ivermectin in clinical trials, demonstrating superior efficacy and comparable safety. Continue reading “Moxidectin, First New Treatment for River Blindness in 30 Years, Approved by FDA”

Advertisements

Weekly Pharmacology News Round-Up: June 8th – June 14th 2018

This week’s clinical pharmacology highlights include a new treatment for river blindness, further success for JAK inhibitors in inflammatory diseases, and the finding that more patients are taking medications associated with depressive symptoms.

Continue reading “Weekly Pharmacology News Round-Up: June 8th – June 14th 2018”